ABSTRACT
OBJECTIVES: To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID). METHODS: Multicentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis. These variables were compared between the baseline, and first week, first, third, sixth months, first and second year. RESULTS: We studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6±11.7 years. The IMID included were: spondyloarthritis (n=43), Behçet's disease (n=10), psoriatic arthritis (n=8), Crohn's disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1), CONCLUSIONS: CZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs.
Subject(s)
Immunosuppressive Agents , Uveitis , Male , Humans , Female , Adult , Middle Aged , Certolizumab Pegol/adverse effects , Follow-Up Studies , Treatment Outcome , Immunosuppressive Agents/adverse effects , Uveitis/diagnosis , Uveitis/drug therapy , Uveitis/etiologyABSTRACT
OBJECTIVES: To assess the plasma apolipoprotein B/apolipoprotein A1 ratio and its potential association with cardiovascular events (CVE) in patients with rheumatoid arthritis (RA). METHODS: A baseline analysis was made of the CARdiovascular in rheuMAtology Project (CARMA), a 10-year prospective study evaluating the presence of at least one CVE in 775 Spanish patients with RA. Of them, 29 had already experienced CVE prior to the inclusion in the study. We assessed the association between the elevation of the apoB/apoA1 ratio with the presence of CVE according to a logistic regression model for possible confounding factors. We also analysed the main parameters of activity of RA and parameters related to lipid metabolism. RA patients were classified according to treatment: patients treated with disease-modifying anti-rheumatic drugs without biologics and those undergoing biologic therapy (anti-TNF-α, anti-IL-6 receptor, and other biologic agents). RESULTS: The apoB/apoA1 ratio of patients who had experienced CVE was higher than that of patients without previous CVE (0.65 vs. 0.60). However, the difference between both subgroups did not reach statistical significance (p=0.197). It was also the case after the multivariate analysis [OR: 1.48 (95% CI: 0.15-14.4); p=0.735]. RA patients from the group with CVE were more commonly receiving lipid-lowering treatment with statins than those without CVE history (41.4% vs. 20%, p=0.005). High HAQ and high atherogenic index were significantly associated with the presence of CVE. There was no statistical association between the type of biologic therapy used in RA and the presence of CVE. CONCLUSIONS: No association between ApoB/apoA1 ratio and CVE was found at the baseline visit of patients with RA from the CARMA study.
Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Cardiovascular Diseases , Apolipoprotein A-I , Apolipoproteins B , Humans , Prospective Studies , Tumor Necrosis Factor-alpha/therapeutic useABSTRACT
No disponible
Subject(s)
Humans , Male , Young Adult , Ribs/abnormalities , Ribs/diagnostic imaging , Pain/diagnostic imagingABSTRACT
No disponible
Subject(s)
Humans , Female , Middle Aged , Sjogren's Syndrome/complications , Arthritis, Rheumatoid/complications , Nephrocalcinosis/diagnostic imaging , Vitamin D Deficiency/diagnosis , Renal Colic/diagnosisSubject(s)
Cervical Rib/abnormalities , Adult , Cervical Rib/diagnostic imaging , Humans , Male , RadiographySubject(s)
Humans , Male , Adult , Exanthema/chemically induced , Exanthema/therapy , Fever/drug therapy , Fever/etiology , /chemically induced , /complications , /therapy , Allopurinol/administration & dosage , Allopurinol/adverse effects , Adrenal Cortex Hormones/therapeutic use , Abdominal Pain/complications , Radiography, Abdominal , Biopsy , Exanthema/complications , Splenomegaly/complications , Radiography, Thoracic , Transaminases/analysis , Hyperuricemia/complications , Hyperuricemia/diagnosisABSTRACT
No disponble
Subject(s)
Humans , Male , Middle Aged , Low Back Pain/complications , Low Back Pain/diagnosis , Aortic Aneurysm/complications , Aortic Aneurysm/diagnosis , Aortic Rupture/complications , Aortic Rupture/diagnosis , Prednisone/therapeutic use , Diclofenac/therapeutic use , Dipyrone/therapeutic use , Tramadol/therapeutic use , Aortic Rupture/physiopathology , Aortic Rupture , Diagnosis, Differential , Hypotension/complicationsABSTRACT
Las manifestaciones oculares en el lupus eritematoso sistémico (LES) son relativamente frecuentes, con mayor prevalencia de la queratoconjuntivitis seca. Sin embargo, la aparición de exoftalmos unilateral secundario a pseudotumor orbitario en pacientes con LES es extremadamente rara 17, y en ocasiones puede presentarse refractaria al tratamiento farmacológico convencional (glucocorticoides e inmunosupresores). A continuación presentamos el caso de una paciente con LES y pseudotumor orbitario refractario a tratamiento con ciclofosfamida y excelente respuesta clínica con desaparición de la clínica oftalmológica tras el inicio de la terapia con rituximab(1gx2), eficacia mantenida tras la infusión de dos ciclos completos sin incidencias (AU)
Ocular manifestations in Systemic Lupus Erythematosus(SLE)are relatively frequent, with a major prevalence of the Keratoconjunctivitis sicca. Nevertheless, the appearance of unilateral exophthalmos secondary to orbital pseudotumor in patients with SLE is extremely rare 17, and on occasion it can be refractory to conventional pharmacological treatment(glucocorticoids and immunosuppressants). We present the case of a patient with SLE and orbital pseudotumor refractory to treatment with Cyclophosphamide(CF) and an excellent clinical response, with disappearance of the ophthalmological condition after the beginning of the rapy with Rituximab (1gx2), continuing after the infusion of two complete cycles without incidents (AU)
Subject(s)
Humans , Female , Middle Aged , Lupus Erythematosus, Systemic/complications , Lupus Erythematosus, Systemic/drug therapy , Exophthalmos/complications , Exophthalmos/diagnosis , Exophthalmos/drug therapy , Orbital Pseudotumor/complications , Immunosuppressive Agents/therapeutic use , Glucocorticoids/therapeutic use , Lupus Erythematosus, Systemic/physiopathology , Magnetic Resonance Imaging , Adrenal Cortex Hormones/therapeutic useABSTRACT
Ocular manifestations in Systemic Lupus Erythematosus (SLE) are relatively frequent, with a major prevalence of the Keratoconjunctivitis sicca. Nevertheless, the appearance of unilateral exophthalmos secondary to orbital pseudotumor in patients with SLE is extremely rare(1-7), and on occasion it can be refractory to conventional pharmacological treatment (glucocorticoids and immunosuppressants). We present the case of a patient with SLE and orbital pseudotumor refractory to treatment with Cyclophosphamide (CF) and an excellent clinical response, with disappearance of the ophthalmological condition after the beginning of therapy with Rituximab (1g×2), continuing after the infusion of two complete cycles without incidents.
ABSTRACT
La afección renal es infrecuente en la esclerosis sistémica, a diferencia de otras colagenosis. La aparición de síndrome nefrótico se ha relacionado con el uso de fármacos, especialmente la D-penicilamina, o raramente como manifestación de amiloidosis secundaria, bastante infrecuente en la esclerosis sistémica. Presentamos un caso de síndrome nefrótico en una paciente con esclerosis sistémica, producido por una glomerulonefritis membranosa, descrito de forma excepcional en la literatura (AU)
The renal affectation is infrequent in scleroderma, unlike other collagen diseases. The appearance of nephrotic syndrome has been related to the drug use, specially the D-penicilamine, or rarely as a manifestation of secondary amilodosis, quite infrequent in scleroderma. We report a case of nephrotic syndrome in a patient with systemic scleroderma, produced by a membranous glomerulonephritis, exceptionally described in literature (AU)
Subject(s)
Humans , Female , Middle Aged , Nephrotic Syndrome/complications , Scleroderma, Diffuse/complications , Glomerulonephritis, Membranous/complications , Enkephalin, D-Penicillamine (2,5)-/adverse effects , Amyloidosis/complicationsABSTRACT
The renal affectation is infrequent in scleroderma, unlike other collagen diseases. The appearance of nephrotic syndrome has been related to the drug use, specially the D-penicilamine, or rarely as a manifestation of secondary amilodosis, quite infrequent in scleroderma. We report a case of nephrotic syndrome in a patient with systemic scleroderma, produced by a membranous glomerulonephritis, exceptionally described in literature.
